Randomised trial of intrapleural urokinase in the treatment of childhood empyema
- PMID: 11923554
- PMCID: PMC1746300
- DOI: 10.1136/thorax.57.4.343
Randomised trial of intrapleural urokinase in the treatment of childhood empyema
Abstract
Background: The role of intrapleural fibrinolytic agents in the treatment of childhood empyema has not been established. A randomised double blind placebo controlled trial of intrapleural urokinase was performed in children with parapneumonic empyema.
Methods: Sixty children (median age 3.3 years) were recruited from 10 centres and randomised to receive either intrapleural urokinase 40 000 units in 40 ml or saline 12 hourly for 3 days. The primary outcome measure was length of hospital stay after entry to the trial.
Results: Treatment with urokinase resulted in a significantly shorter hospital stay (7.4 v 9.5 days; ratio of geometric means 1.28, CI 1.16 to 1.41 p=0.027). A post hoc analysis showed that the use of small percutaneous drains was also associated with shorter hospital stay. Children treated with a combination of urokinase and a small drain had the shortest stay (6.0 days, CI 4.6 to 7.8).
Conclusion: Intrapleural urokinase is effective in treating empyema in children and significantly shortens hospital stay.
Comment in
-
Urokinase in the treatment of childhood empyema.Thorax. 2003 Jan;58(1):93; author reply 93-4. doi: 10.1136/thorax.58.1.93-a. Thorax. 2003. PMID: 12511733 Free PMC article. No abstract available.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical